O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
Titel:
O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
Auteur:
Shitara, K. Bang, Y. Iwasa, S. Sugimoto, N. Ryu, M. Sakai, D. Chung, H. Omuro, Y. Kawakami, H. Yabusaki, H. Sakamoto, Y. Nishina, T. Inaki, K. Kuwahara, Y. Suto, F. Sugihara, M. Saito, K. Kojima, A. Yamaguchi, K.